Nidogen 2 Proteins (NID2)

Human Nidogen 2 (NID2) interaction partners

1. High NID2 methylation is associated with non-small cell lung cancer.

2. the serum NID2 levels show significant elevation in the ESCC patients and those with relatively high serum NID2 levels ( 32.6 mu mu g/L) are significantly associated with poor survival outcome compared with those with very low serum NID2 levels (< < 20.0 mu mu g/L).

3. Addition of a TWIST1/NID2-based DNA methylation assay adds diagnostic value to urine cytology and the model is sensitive to the classification of equivocal cytology.

4. Promoter methylation of NID2 was significantly higher in nasopharyngeal carcinoma and esophageal squamous cell carcinoma cells. NID2 suppresses the EGFR/Akt and integrin/FAK/PLCgamma metastasis-related pathways.

5. Knockdown of nidogen-2 reduced SOX9 expression, whereas it up-regulated RUNX2 expression

6. The cleavage of nidogen-1 and -2 is partially inhibited in human tumor samples.

7. combined methylation analysis of Twist homolog 1 and nidogen-2 genes may be a simple, noninvasive, sensitive, and specific method for detecting cancer cells in urine.

8. Decreased nidogen-2 expression is associated with hepatocellular carcinoma

9. NID2 promoter hypermethylation is associated with oral cavity squamous cell carcinoma.

10. Nidogen-2 is a new biomarker for ovarian cancer which correlates closely with CA125.

11. short arm region of laminin-5 gamma2 chain: structure, mechanism of processing and binding to heparin, nidogen-1, fibulin-1 and fibulin-2

12. found to be ubiquitous component of basement membrane zones underneath developing epithelia of most of the major organ systems; may participate in cell biological functions during human development

13. Nidogen-2 compensation hypothesis to explain limited phenotype observed following elimination of nidogen-1 gene.

14. nidogen-2 is equivalent to nidogen-1 in skin-organotypic coculture, and both can promote the development of a functional basement membrane zone

15. CpG islands of both NID1 and NID2 genes are aberrantly methylated in human cancer samples and cancer cell lines.